The Influence of Obesity on Prostate Cancer Diagnosis and Treatment

Piotr Bryniarski, Andrzej Paradysz and Mieczysław Fryczkowski
*Medical University of Silesia in Katowice, Department of Urology in Zabrze
 Poland*

1. Introduction

To date there were only a few risk factors for developing prostate cancer (Pca) like advanced age, skin color and family history (Crawford, 2003). For the long time obesity was considered a negative feature which may contribute to chronic diseases like hypertension or diabetes, but its relationship with cancers was unknown. Last years revealed the obvious truth that such relationship exists and may be very strong. The problem seems to be very important given that obesity is very common, especially in western countries.

Over the past 25 years, the number of obese men has increased from 15% to 30% in USA. In 2000 66% of adults in U.S were classified as overweight or obese (Flegal et al., 2002). Nowadays no one denies that overweight and obesity is an independent risk factor for developing colon cancer or post-menopausal breast cancer.

Relationship with other cancers is still discussed especially in case of Pca. While the connection between obesity and chronic internal diseases is simple to explain, its relation to cancers is not so unequivocal. Most theories indicate the permanent chronic inflammation in obese which may contribute to oncogenesis.

Dishormonose observed in obese consists of high levels of insulin, insulin growth factor - 1 (IGF-1) (Chan et al., 1998, 2002), leptin, estrogens, and low levels of androgens. Insulin and IGF -1 are strong mitosis activators which may explain such "oncopotential". On the other hand low levels of testosterone and high of estrogen should protect men from developing Pca. It is only a simple example why the relation between obesity and prostate cancer may be very complex.

2. Nutrition

Several products are thought to be associated with increased risk for developing prostate cancer, others are known to act protectively. To the first group we may include saturated fats, red meat and dairy products (Kondo et al., 1994; Shirai, et al., 1997; Tornaiainen et al., 2007). In the second group we will find vitamin A, D and E, selenium, lycopene, fitoestrogens and isoflavones (Clark et al., 1998; Heinonen et al., 1998; Imaida et al., 2001; Kato et al., 2000; Schwartz et al., 1990). Vitamin A, D, E, selenium, lycopene and fitoestrogens are the compounds of fruits, vegetables, soya and tea. Vitamin A is known to improve cell apoptosis (Pienta et al., 1993; Young et al., 1994). Vitamin D facilitates cell differentiation (Hedlund et al., 1997). It was hypothesized that it may increase PSA

doubling time (PSA DT) (Beer et al., 2003). Selenium is a known antioxidant (Clark et al., 1996). In Asia, where soya and tea consumption (fitoestrogens) is higher in comparison to western countries, the prevalence of prostate cancer is lower (Adlercreutz et al., 1993; Fotsis et al., 1993). Several studies tried to prove the favorable impact of vitamin E in Pca prevention (Knekt et al., 1990; The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group, 1994).

However, it has to be stressed that such influences are still rather hypothesis than evidence based facts. SELECT (Selenium and Vitamin E Comparison Trial) trial failed to demonstrate the favorable impact of selenium and vitamin E on Pca morbidity (Ledema et al., 2011).

3. Obesity

It is of paramount significance to distinguish between high-risk and low-risk patients depending on extent of obesity. There are many ways to determine the range of overweight and obesity. The most prevalent is body mass index developed by World Health Organization. However, it does not differentiate fat mass from muscle mass. That is why waist - hip ratio (WHR) is more commonly applied while assessing the central adiposity, and correlates much stronger with hormonal alterations (the importance of that finding is emphasized later in the text) than BMI.

There are various theories concerning the influence of obesity on the natural development, diagnostics or progression after radical treatment of Pca. The Health Professional Follow-Up Study was based on 47757 men who were observed for 14 years and showed that relative risk for developing prostate cancer was 0,52 in obese compared to non-obese men (Giovannucci et al., 2003).

The 5 times increased percentage of biochemical recurrence after radical prostatectomy observed in Afro-Americans, compared to Euro-Americans, is sometimes explained by 3 times more frequent presence of overweight or obesity among the former. It also may result from the polymorphism of the androgen receptor which causes higher PSA concentration in Afro-Americans. On the other hand two large studies failed to demonstrate disastrous impact of obesity on prostate cancer morbidity (Andersson et al., 1997; Rapp et al., 2005).

Not only the absolute value of BMI seems to be important when assessing the patient's risk. It was shown that also gaining weight at the greatest rate of ≥ 1.5 kg/year between 25 years of age and time of Pca diagnosis will result in more rapid biochemical failure after radical treatment (Strom et al., 2005).

The influence of obesity on Pca is definitely negative, including the following:

1. dishormonose – abnormal hormone concentrations, which induces the intensification of diagnostics and at the same time postpones proper treatment
2. comorbidities, which pushes the prostate diagnostics into the background and consequently patients suffer from more advanced forms of prostate cancer
3. difficulties in per rectum examination in obese patients,
4. difficulties during transrectal ultrasound (TRUS) of the prostate and prostate biopsy (due to larger prostates in obese patients) (Freedland et al., 2006).
5. difficulties during radical prostatectomy and radical radiotherapy due to:
 - a. technical problems (larger hooks, smaller operational field)
 - b. larger prostates observed in obese patients (much problem while conducting nerve-sparing technique)

6. Unfavorable postoperative features especially higher rate of:

- a. high grade disease
- b. positive surgical margins
- c. extraprostatic extension (pT3a)
- d. lymph node metastases (N+)
- e. biochemical recurrence
- f. fatal disease

7. hemodilution (explained later)

Lastly it was proved that the unfavorable impact of obesity on Pca may be explained by genetic examinations. It was hypothesized that the AA genotype of rs9939609, which is associated with an increase in BMI, would protect against non-aggressive prostate tumors whilst increasing the risk of aggressive prostate tumors (Lewis et al., 2010). The abovementioned study gave us only weak proof of such correlation.

4. Prostate cancer cells and adipocytes

Skeletal metastases are most common in advanced Pca. Metastases are known to be osteoblastic ones. Prostate cancer cells are absorbing lipids directly to develop and progress, that is why bone marrow is so common place of metastases.

It was also experimentally shown that bone marrow without adipocytes is less attractive for prostate cancer cells to reside (Brown et al., 2006). It was even suggested that lowering lipid levels with statins will impact the progression of prostate cancer, but this assumption turned out not to be true (Platz et al., 2006).

5. Sex hormones

As stated in the introduction in obese levels of sex hormones are different from that observed in normal weight people. Prostate is hormone-sensitive gland and therefore androgens are needed for its development.

Also prostate cancer is hormone-sensitive and testosterone is known to accelerate its progression to advanced and metastatic form while estrogens inhibit such progress. This finding led us to application of castration (surgical or pharmacological) in the treatment of advanced or metastatic prostate cancer.

However, the relation between dishormones and prostate cancer is not so unequivocal. Testosterone also influences the differentiation of prostate cells (but not prostate cancer cells) to mature forms, while estrogens have contrary impact and therefore may lead to poorly differentiated Pca (Massengill et al. 2003; Schatzl et al., 2001).

6. Aggressive prostate cancer

It is also assumed that PCa in overweight people is more aggressive. Usually it was stated that Pca with Gleason score > 7 was significantly more frequent in obese patients. Not all authors agree with that hypothesis (Chyou et al., 1994; Major et al., 2011; Nilsen et al., 1999; Rodriguez et al., 2007; Schuurman et al., 2000; Snowdon et al., 1984).

Authors emphasize that central obesity as the outcome of excessive fat accumulation results in glucose intolerance, high blood pressure, atherosclerosis, cardiovascular disease, insulin resistance, altered metabolic profile, metabolic syndrome, and obesity-related lipid

disorders (Hsing et al., 2007). Especially insulin resistance, higher IGF-1 and leptin levels are recognized responsible for such aggressiveness (Hedlund et al., 1994; Prabhat et al., 2010). IGF-1 is involved in angiogenesis, responsible for bone metastases and developing androgen-independent progression of Pca. Leptin is responsible for cell migration and growth factor expression in hormone-resistant cells of Pca.

It is not proven that worse treatment outcomes in obese patients are due to unfavorable features of prostate cancer itself. In one of the studies it was reported that obesity was positively correlated with clinical progression independently of prostate cancer grade, stage and primary treatment (Gong et al., 2007).

Higher rate of cancer progression is also due to unfavorable features of obese men after radical prostatectomy. It was proven that increased BMI is associated with high grade disease, positive surgical margins, extraprostatic extension of the disease and lymph node metastases. Biochemical recurrence after radical prostatectomy is also more frequent in obese patients compared to non-obese men (Freedland et al., 2005).

7. Androgen deprivation therapy (ADT)

Pharmacological castration with GnRH agonists is the standard treatment for patients with locally advanced or metastatic Pca. However, it is burdened with several adverse effects like osteoporosis, loss of libido, erectile dysfunction and finally metabolic syndrome. Increased levels of total cholesterol, LDL and decreased HDL, diabetes and hypertension contribute to higher risk of acute coronary syndrome (ACS).

Obese patients receiving ADT are at highest risk for developing ACS as ADT therapy and obesity shares the cardiovascular risk through the metabolic syndrome. They should be constantly monitored and treated accordingly (Cleffi et al., 2011). Osteoporosis in Pca is not only the result of cancer itself. Osteoblastic metastases of prostate cancer contribute to pathologic spine fractures which may be fatal eventually. Immediate spine decompression in orthopedics department is indicated in such condition.

The situation may be worse when patient is given ADT. It was proven that hypogonadism leads to osteopenia and finally to osteoporosis. As obese patients have lower levels of testosterone, abovementioned unfavorable factors may contribute to pathologic fractures.

To prevent such mournful course patients are advised to take bisphosphonates (alendronic, zoledronic, clodronic acid, etc.) or denosumab (RANK ligand inhibitor) which inhibit osteoclasts and slow down progression of the disease.

8. Hemodilution

Undoubtedly, a negative feature of PSA concentration is the fact that it is subject to hemodilution. Some authors claim that in overweight and obese patients PSA concentration is lower, which is, in the first place, caused by the aforementioned phenomenon. This phenomenon is supposed to consist in the dissolution of PSA mass in a large amount of plasma, finally resulting in lower PSA concentration. PSA is a protease which physiological function consists in liquefying semen.

Every man is characterized by a quite invariable amount (mass) of this secreted into the blood protein, depending on age, the size of prostate, the presence of cancer or other prostate diseases. However, standard PSA determination means that PSA mass is dissolved

in plasma volume which is mainly dependant on the obesity extent. This led some authors to explore new markers independent of hemodilution (Bryniarski et al., 2011). PSA mass meets these criteria, but further studies are needed to demonstrate its superiority over standard PSA concentration.

9. Author's contribution

Hereby we present our work on hemodilution (Bryniarski et al., 2011). The aim of our study was to prove the superiority of PSA mass over standard PSA concentration in predicting biochemical recurrence after radical prostatectomy.

9.1 Material and methods

From 1994 until the end of 2007 206 radical retropubic prostatectomies in Caucasian men suffering from prostate cancer were carried out in the Department of Urology in Zabrze, Medical University of Silesia in Katowice. The patients who underwent preoperative anti-androgen therapy, chemotherapy or radiotherapy were excluded from the research (29 patients).

177 patients were qualified for the research. In our group two types of data were subject to analysis. Preoperative data, such as: age, height, weight, BMI, PSA concentration (immunoenzymatic Elecsys test; Cobas 6000 Hitachi) and postoperative data: the extent of histopathologic differentiation of prostate tissue in Gleason score, extracapsular extension (pT3), the presence of lymph nodes metastases and the presence of positive surgical margins.

Patients are under constant control in the Hospital Outpatient Clinic, thanks to which data concerning progression (biochemical recurrence, local recurrence, death) were also collected and the cancer-specific survival time was determined. The total volume of plasma and the PSA mass were calculated on the basis of the formulas (Table 1) (Boer, 1984; Du Bois & Du Bois, 1916).

Estimated Body Surface (EBS)	Plasma volume [liters] (PV)	PSA mass [μg]
$(\text{weight})^{0.425} \times (\text{height})^{0.72} \times 0,007184$	$\text{EBS} \times 1,670$	$\text{PV} \times \text{PSA concentration}$

Table 1. The formulas to estimate plasma volume and PSA mass.

The group of 177 patients was divided according to:

1. BMI – into 3 groups: I – 45 patients with normal weight ($\text{BMI} < 25$), II – 95 overweight patients ($\text{BMI} = 25 - 29,9$), III – 37 obese patients ($\text{BMI} \geq 30$).
2. Preoperative PSA concentration – into 3 groups: I – 79 patients with $\text{PSA} < 10 \text{ ng/ml}$, II – 66 patients with $\text{PSA} 10 - 19,9 \text{ ng/ml}$, III – 32 patients with $\text{PSA} \geq 20 \text{ ng/ml}$.
3. Preoperative PSA mass – into 3 groups: I – 71 patients with $\text{PSA} < 40 \text{ μg}$, II – 78 patients with $\text{PSA} 40 - 69,9 \text{ μg}$ and III – 28 patients with $\text{PSA} \geq 70 \text{ μg}$.

The characteristics of each group is shown in tables 2 and 3.

		BMI (kg/m ²)			PSA (ng/ml)			PSA mass (µg)		
		I	II	III	I	II	III	I	II	III
Age (years)	mean	62,8	62,2	62,1	63	61,4	62,6	62,8	61,8	62,7
	SD	6,7	5,9	6	5,7	6,9	5,5	5,8	6,5	6
	range	50-76	48-74	49-71	49-74	48-76	52-72	49-74	48-76	52-72
BMI (kg/m ²)	mean	23,4	27,4	32,6	27,1	28	27,4	26,9	27,8	28,2
	SD	1,4	1,3	2,3	2,9	4	3,3	2,9	3,6	4
	range	17,9-24,9	25-29,9	30,1-40,3	20-37,5	17,9-40,3	22,1-35	20-37,5	17,9-40,3	22,1-38
Plasma volume (liters)	mean	3,1	3,2	3,45	3,2	3,3	3,2	3,2	3,2	3,2
	SD	0,13	0,2	0,2	0,2	0,2	0,2	0,2	0,2	0,2
	range	2,9-3,4	2,8-3,9	2,9-4,1	2,7-3,7	2,8-4,1	2,9-3,7	2,7-3,7	2,8-4,1	2,9-3,9
PSA concentration (ng/ml)	mean	12,8	14,1	14,2	6,4	14,2	31,3	6,1	14,1	32,6
	SD	8,9	11,9	7,7	1,9	2,8	11,6	1,7	3,5	11,9
	range	2,8-51,8	1,8-61,7	4,2-43,4	1,8-9,8	10-19,8	20,4-61,7	1,8-9,6	9-21,8	18-61,7
Gleason score	median	5	6	6	5	6	6	5	6	6
PSA mass (µg)	mean	56,6	46,2	48,9	20,8	47	101,1	19,7	46,2	106,7
	SD	27,4	39	25,1	6,37	10,3	37,1	5,6	11,3	36,5
	range	31,9-156,6	6,5-196,6	13,7-129,5	6,5-32,7	30,3-71	64,2-196,6	6,5-29,8	30,3-69,6	70,7-196,6

Table 2. Characteristics of patients in groups of BMI, PSA concentration and PSA mass.

All constant variables distributions were analyzed with regard to normality by means of Kolmogorov-Smirnov and Lilliefors tests. By means of descriptive statistics the following characteristics have been determined: mean or median, standard deviation as well as maximal and minimal value.

In order to determine differences between the groups, where variables are of categorical character, Chi-square test has been used. In order to determine differences between a number of independent groups, where continuous variables have distribution other than normal, Kruskal-Wallis test has been used.

In order to eliminate the influence of factors disrupting the correlation between BMI and PSA concentration, such as: age, the extent of prostate cancer differentiation in Gleason score, extracapsular extension (pT3) or positive surgical margins, multiple regression has been used to create a model which would describe the aforesaid relationship. The aforementioned disrupting factors have been incorporated into the model.

		BMI (kg/m ²)			PSA concentration (ng/ml)			PSA mass (µg)		
		I	II	III	I	II	III	I	II	III
pT3	Yes	12 (18,1%)	33 (50%)	21 (31,9%)	14 (21,2%)	32 (48,5%)	20 (30,3%)	13 (19,6%)	34 (51,5%)	19 (28,7%)
	No	33 (29,7%)	62 (55,8%)	16 (14,5%)	65 (58,5%)	34 (30,6%)	12 (10,9%)	58 (52,2%)	44 (39,6%)	9 (8,1%)
Positive lymph nodes	Yes	2 (20%)	4 (40%)	4 (40%)	1 (10%)	5 (50%)	4 (40%)	1 (10%)	3 (30%)	6 (60%)
	No	43 (25,7%)	91 (54,5%)	33 (19,8%)	78 (46,7%)	61 (36,5%)	28 (16,7%)	70 (41,9%)	75 (44,9%)	22 (13,1%)
Positive surgical margin	Yes	13 (26%)	28 (56%)	9 (18%)	9 (18%)	27 (54%)	14 (28%)	7 (14%)	29 (58%)	14 (28%)
	No	32 (25,1%)	67 (52,7%)	28 (22%)	70 (55,1%)	39 (30,7%)	18 (14,1%)	64 (50,3%)	49 (38,5%)	14 (11%)
Biochemical recurrence	Yes	13 (20%)	34 (52,3%)	18 (27,6%)	15 (23%)	30 (46,1%)	20 (30,7%)	14 (21,5%)	33 (50,7%)	18 (27,6%)
	No	32 (28,5%)	61 (54,4%)	19 (16,9%)	64 (57,1%)	36 (32,1%)	12 (10,7%)	57 (50,8%)	45 (41,1%)	10 (8,9%)
Local recurrence	Yes	4 (20%)	10 (50%)	6 (30%)	5 (25%)	9 (45%)	6 (30%)	5 (25%)	7 (35%)	8 (40%)
	No	41 (26,1%)	85 (54,1%)	31 (19,7%)	74 (47,1%)	57 (36,3%)	26 (16,5%)	66 (42%)	71 (45,2%)	20 (12,7%)
Death	Yes	1 (6,6%)	6 (40%)	8 (53,3%)	1 (6,6%)	10 (66,6%)	4 (26,6%)	0 (0%)	9 (60%)	6 (40%)
	No	44 (27,1%)	89 (54,9%)	29 (17,9%)	78 (48,1%)	56 (34,5%)	28 (17,2%)	71 (43,8%)	69 (42,5%)	22 (13,5%)

Table 3. Characteristics of patients in groups of BMI, PSA concentration and PSA mass.

In order to evaluate and compare the odds ratio of biochemical recurrence together with the elevated concentration and mass of the PSA, the model of logistic regression has been used. The model has been adjusted to Gleason score (<8 and ≥ 8) in postoperative specimen. As both the concentration and the PSA mass did not show normal distribution, the logarithmic (decimal) transformation of data has been performed. 10 patients who have been diagnosed with metastases in the surrounding lymph nodes have been removed from the model because the presence of metastases would distort the results of the observation.

Cancer-specific survival of patients has been evaluated by means of Kaplan-Meier analysis, while the significance of differences between them has been evaluated by means of Gehan's Wilcoxon test.

Receiver operating characteristic (ROC) curves compared predictive variables.

For all statistical tests the critical level of significance has been adopted at $p < 0,05$. The statistical analysis has been calculated by means of StatSoft Statistica 8.0.

9.2 Results

The values PSA mass in the research has a statistically significant influence on extracapsular extension ($p < 0,001$), the presence of metastases in the surrounding lymph nodes ($p < 0,001$), the frequency of positive surgical margins ($p < 0,001$), the presence of biochemical ($p < 0,001$) and local recurrence ($p < 0,001$) and the rate of death ($p < 0,001$).

The research has shown that BMI does not influence preoperative PSA concentration and PSA mass (Fig.1 and 2). Differences in preoperative PSA concentration between the 3 groups of patients are statistically insignificant ($p = 0,28$). The total plasma volume is higher in obese patients ($p < 0,001$).

Fig. 1. Comparison of preoperative PSA concentration (ng/ml) in BMI groups.

Fig. 2. Comparison of preoperative PSA mass in BMI groups.

The model of multiple regression has proved the lack of statistically significant correlation between preoperative PSA concentration and BMI ($p = 0,99$). The research has proved that the elevated preoperative value of PSA mass ($p = 0,02$) is the factor which influences the cancer-specific survival of patients with prostate cancer after RP (Fig.3).

Fig. 3. Comparison of overall survival time (days) in patients with prostate cancer depending on the PSA mass.

Fig. 4. Three-dimensional model of logistic regression with two independent variables (Gleason score and decimal logarithm from the value of PSA mass) and dependent dichotomic variable (biochemical recurrence).

The odds ratio of biochemical recurrence, with the PSA mass increased 10 times, is equal to 8,64 (95% CI: 2,54 – 29,3; $p < 0,001$) (Fig. 4). The odds ratio of biochemical recurrence, with the PSA concentration increased 10 times, is equal to 7,66 (95% CI: 2,25 – 26; $p < 0,001$).

ROC curves for preoperative PSA mass and PSA concentration showed an area under curve (AUC) of 0,72 and 0,65 respectively for biochemical recurrence after RP (Fig. 5). The difference between these two predictors (AUC) was statistically significant ($p = 0,04$).

Fig. 5. ROC curves for PSA mass as a preoperative predictor of biochemical recurrence after RP (Area Under Curve - 0,72).

9.3 Discussion

There are various theories concerning the influence of obesity on the natural development, diagnostics or progression after radical treatment of prostate cancer. The 5 times increased percentage of biochemical recurrence observed in Afro-Americans, compared to Euro-Americans, is sometimes explained by 3 times more frequent presence of overweight or obesity among the former (Spangler et al., 2007).

Its influence is definitely negative, including the following:

1. difficulties in per rectum examination in obese patients (Bray, 2006),
2. dishormonose (Hsing et al., 2002; Kaaks et al., 2000) – abnormal hormone concentrations, which induces the intensification of diagnostics and at the same time postpones proper treatment,
3. comorbidities, which pushes the prostate diagnostics into the background and consequently patients suffer from more advanced forms of prostate cancer

Some authors suggest another factor, namely, lower PSA concentration in obese patients (Baillargeon et al., 2005). The consequence of the aforesaid correlation may impact on prostate cancer diagnosis and evaluation of progression after its radical treatment. Other authors disclaim the abovementioned connection (Freedland et al., 2006).

The authors who prove that obese patients are characterized by lower PSA concentration, refer to the phenomenon of hemodilution. The supporters of that theory claim that obesity is characterized by a larger amount of circulating blood, so theoretically the constant PSA mass circulating in the organism would be dissolved in a large amount of plasma, resulting in a lower PSA concentration.

However, our research has not proved that the elevated BMI has a significant influence on the preoperative PSA concentration. In order to explain the inconsistency we will call upon racial differences between the analyzed groups. The following research has been done on a group of patients of Caucasian race, while the aforesaid research has been frequently based on ethnically heterogeneous groups. The cause of differences between the outcomes can result from the polymorphism of the androgen receptor which causes higher PSA concentration in Afro-Americans, as well as statistically significant bigger obesity of this group (Xu et al., 2002). The influence of ethnical differences can, of course, be dismissed by appropriate statistical manipulations, nevertheless, it seems that research done on homogenous groups is characterized by greater statistical power.

In order to exclude the potential influence of hemodilution on the PSA concentration, the PSA mass in each patient has been calculated. Thanks to mathematical formulas used to estimate the total amount of circulating blood, its amount can be quite precisely determined. It has to be underlined that the phenomenon of hemodilution in obese patients had no statistically significant influence on PSA concentration. Also, having excluded other factors influencing PSA concentration, such as: cancer differentiation in Gleason score, the extracapsular extension (pT3), positive surgical margins or the patient's age, no significant correlation between BMI and the preoperative PSA concentration has been found.

However, comparing both parameters (PSA concentration and the PSA mass) it has to be stressed that the probability of biochemical recurrence after RP is better predicted by PSA mass, which surely results from the fact that the PSA mass includes the element eliminating the phenomenon of hemodilution. Despite the fact that both preoperative parameters "equally well" evaluate the progression after RP, the PSA mass seems to be a little more sensitive parameter (which is indicated by the difference in the odds ratio and AUC).

9.4 Conclusions

1. Increased preoperative value of the PSA mass is connected with:
 - a. more frequent cancer diagnosis of pT3 prostate cancer,
 - b. more frequent diagnosis of metastases in the surrounding lymph nodes,
 - c. more frequent recognition of the positive surgical margin,
 - d. shorter cancer-specific survival time,
 - e. higher percentage of progression.
2. The preoperative PSA mass is a better predictor of biochemical recurrence after RP than PSA concentration.
3. The total plasma volume is higher in obese patients, however, it does not influence the preoperative PSA concentration significantly.

10. References

- Crawford, ED. (2003). Epidemiology of prostate cancer. *Urology*. Vol. 62, No. 6, (December 2003), Supplement 1, pp. 3-12, ISSN 0090-4295
- Flegal, KM., Carroll, MD., Ogden, CL. & Johnson, CL. (2002). Prevalence and trends in obesity among US adults, 1999-2000. *JAMA*. Vol. 288, No. 14, (October 2002), pp. 1723-7, ISSN 0098-7484
- Chan, JM., Stampfer, MJ., Giovannucci, E., Gann, PH., Ma, J., Wilkinson, P., Hennekens, CH. & Pollak, M. (1998). Plasma insulin like growth factor-I and prostate cancer risk: a prospective study. *Science*. Vol. 279, No. 5350, (January 1998), pp. 563-6, ISSN 0036-8075
- Chan, JM., Stampfer, MJ., Ma, J., Gann, P., Gaziano, JM., Pollak, M. & Giovannucci, E. (2002). Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. *J Natl Cancer Inst*. Vol. 94, No. 14, (July 2002), pp. 1099-106, ISSN 0027-8874
- Kondo, Y., Homma, Y., Aso, Y. & Kakizoe, T. (1994). Promotional effect of two-generation exposure to a high-fat diet on prostate carcinogenesis in ACI/Seg rats. *Cancer Res*. Vol. 54, No. 23, (December 1994), pp. 6129-32, ISSN 0008-5472
- Shirai, T., Sano, M., Tamano, S., Takahashi, S., Hirose, M., Futakuchi, M., Hasegawa, R., Imaida, K., Matsumoto, K., Wakabayashi, K., Sugimura, T. & Ito, N. (1997). The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. *Cancer Res*. Vol. 57, No. 2, (January 1997) pp. 195-8, ISSN 0008-5472
- Tornaiainen, S., Hedelin, M., Autio, V., Rasinperä, H., Bälter, KA., Klint, A., Bellocco, R., Wiklund, F., Stattin, P., Ikonen, T., Tammela, TL., Schleutker, J., Grönberg, H. & Järvelä, I. (2007). Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and Finland. *Cancer Epidemiol Biomarkers Prev*. Vol. 5, No. 5, (May 2007), pp. 956-61, ISSN 1055-9965
- Kato, K., Takahashi, S., Cui, L., Toda, T., Suzuki, S., Futakuchi, M., Sugiura, S. & Shirai, T. (2000). Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis. *Jpn J Cancer Res*. Vol. 91, No. 8, (August 2000), pp. 786-91, ISSN 0910-5050
- Imaida, K., Tamano, S., Kato, K., Ikeda, Y., Asamoto, M., Takahashi, S., Nir, Z., Murakoshi, M., Nishino, H. & Shirai, T. (2001). Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. *Carcinogenesis*. Vol. 22, No. 3, (March 2001), pp. 467-72, ISSN 0143-3334
- Clark, LC., Dalkin, B., Krongrad, A., Combs, GFJr., Turnbull, BW., Slate, EH., Witherington, R., Herlong, JH., Janosko, E., Carpenter, D., Borosso, C., Falk, S. & Rounder, J. (1998). Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. *Br J Urol*. Vol. 81, No. 5, (May 1998), pp. 730-4, ISSN 0007-1331
- Heinonen, O., Albanes, D. & Virtamo, J. (1998). Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. *J Natl Cancer Inst*. Vol. 90, No. 6, (March 1998), pp. 440-6, ISSN 0027-8874
- Schwartz, GG. & Hulka, BS. (1990). Is vitamin D deficiency a risk factor of prostate cancer? (Hypothesis). *Anticancer Res*. Vol. 10, No. 5A, (September 1990), pp. 1307-11, ISSN 0250-7005

- Pienta, KJ., Nguyen, NM. & Lehr JE. (1993). Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. *Cancer Res.* Vol. 53, No. 2, (January 1993), pp. 224-6, ISSN 0008-5472
- Young, CY., Murtha, PE., Andrews, PE., Lindzey, JK. & Tindall DJ. (1994). Antagonism of androgen action in prostate tumor cell by retinoic acid. *Prostate.* Vol. 25, No. 1, (July 1994), pp. 39-45, ISSN 0270-4137
- Hedlund, TE., Moffatt, KA., Uskokovic, MR. & Miller, GJ. (1997). Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cell in a vitamin D receptor-dependent fashion. *Clin Cancer Res.* Vol. 3, No. 8, (August 1997), pp. 1331-8, ISSN 1078-0432
- Beer, TM., Lemmon, D., Lowe, BA., & Henner, WD. (2003). High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. *Cancer.* Vol. 97, No. 5, (March 2003), pp. 1217-24 ISSN 1097-0142
- Clark, LC., Combs, GF Jr., Turnbull, BW., Slate, EH., Chalker, DK., Chow, J., Davis, LS., Glover, RA., Graham, GF., Gross, EG., Krongrad, A., Leshner, JL Jr., Park, HK., Sanders, BB Jr., Smith, CL. & Taylor JR. (1996). Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. *JAMA* Vol. 276, No. 24, (December 1996), pp. 1957-63, ISSN 0098-7484
- Fotsis, T., Pepper, M., Adlercreutz, H., Fleischmann, G., Hase, T., Montesano, R. & Schweigerer, L. (1993). Genistein, a dietary-derived inhibitor of in vitro angiogenesis. *Proc Natl Acad Sci USA.* Vol. 90, No. 7, (April 1993), pp. 2690-4, ISSN 0027-8424
- Adlercreutz, H., Markkanen, H. & Watanabe, S. (1993). Plasma concentrations of phytoestrogens in Japanese men. *Lancet.* Vol. 342, No. 8881, (November 1993), pp. 1209-10, ISSN 0140-6736
- Knekt, P., Aromaa, A., Maatela, J., Alfthan, G., Aaran, RK., Hakama, M., Hakulinen, T., Peto, R. & Teppo L. (1990). Serum selenium and subsequent risk of cancer among Finnish men and women. *J Natl Cancer Inst.* Vol. 82, No. 10, (May 1990), pp. 864-8, ISSN 0027-8874
- The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. (1994). The effect of vitamin E and 3-carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med.* Vol. 330, No. 15, (April 1994), pp. 1029-35, ISSN 0028-4793
- Ledesma, MC., Jung-Hynes, B., Schmit, TL., Kumar, R., Mukhtar, H. & Ahmad, N. (2011). Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. *Mol Med.* Vol.17, No. 1-2, (January-February 2011), pp. 134-43, ISSN 1076-1551
- Giovannucci, E., Rimm, EB., Liu, Y., Leitzmann, M., Wu, K., Stampfer, MJ. & Willett WC. (2003). Body mass index and risk of prostate cancer in U.S. health professionals. *J Natl Cancer Inst.* Vol. 95, No. 16, (August 2003), pp. 1240-4, ISSN 0027-8874
- Rapp, K., Schroeder, J., Klenk, J., Stoehr, S., Ulmer, H., Concin, H., Diem, G., Oberaigner, W., & Weiland SK. (2005). Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. *Br J Cancer.* Vol. 93, No. 9, (October 2005), pp. 1062-7 ISSN 0007-0920

- Andersson, SO., Wolk, A., Bergström, R., Adami, HO., Engholm, G., Englund, A. & Nyrén O. (1997). Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. *J Natl Cancer Inst.* Vol. 89, No. 5, (March 1997), pp. 385-9 ISSN 0027-8874
- Strom, SS., Wang, X., Pettaway, CA., Logothetis, CJ., Yamamura, Y., Do, KA., Babaian, RJ. & Troncoso P. (2005). Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. *Clin Cancer Res.* Vol. 11, No. 19, (October 2005), pp. 6889-94 ISSN 1078-0432
- Freedland, SJ., Giovannucci, E. & Platz, EA. (2006) Are Findings from Studies of Obesity and Prostate Cancer Really in Conflict? *Cancer Causes Control.* Vol. 17, No. 1, (February 2006) pp. 5-9, ISSN 0957-5243
- Lewis, SJ., Murad, A., Chen, L., Davey Smith, G., Donovan, J., Palmer, T., Hamdy, F., Neal, D., Lane, JA., Davis, M., Cox, A. & Martin RM. (2010) Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. *PLoS One.* Vol. 19, No. 10, (October 2010), pp. e13485 ISSN 1932-6203
- Brown, MD., Hart, CA., Gazi, E., Bagley, S. & Clarke, NW. (2006). Promotion of prostatic metastatic migration towards human bone marrow stroma by Omega 6 and its inhibition by Omega 3 PUFAs. *Br J Cancer.* Vol. 94, No. 6, (March 2006), pp. 842-53, ISSN 0007-0920
- Platz, EA., Leitzmann, MF., Visvanathan, K., Rimm, EB., Stampfer, MJ., Willett, WC. & Giovannucci E. (2006). Statin drugs and risk of advanced prostate cancer. *J Natl Cancer Inst.* Vol. 98, No. 24, (December 2006), pp. 1819-25, ISSN 0027-8874
- Massengill, JC., Sun, L., Moul, JW., Wu, H., McLeod, DG., Amling, C., Lance, R., Foley, J., Sexton, W., Kusuda, L., Chung, A., Soderdahl, D. & Donahue T. (2003). Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. *J Urol.* Vol. 169, No. 5, (May 2003), pp. 1670-5, ISSN 0022-5347
- Schatzl, G., Madersbacher, S., Thurridl, T., Waldmüller, J., Kramer, G., Haitel, A. & Marberger, M. (2001). High-grade prostate cancer is associated with low serum testosterone levels. *Prostate.* Vol. 47, No. 1, (April 2001), pp. 52-8, ISSN 0270-4137
- Snowdon, DA., Phillips, RL. & Choi, W. (1984). Diet, obesity, and risk of fatal prostate cancer. *Am J Epidemiol.* Vol. 120, No. 2, (August 1984), pp. 244-50, ISSN 0002-9262
- Chyou, PH., Nomura, AM. & Stemmermann GN. (1994). A prospective study of weight, body mass index and other anthropometric measurements in relation to site-specific cancers. *Int J Cancer.* Vol. 57, No. 3, (May 1994), pp. 313-7, ISSN 1097-0215
- Rodriguez, C., Freedland, SJ., Deka, A., Jacobs, EJ., McCullough, ML., Patel, AV., Thun, MJ. & Calle, EE. (2007). Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev.* Vol. 16, No. 1, (January 2007), pp. 63-9, ISSN 1055-9965
- Schuurman, AG., Goldbohm, RA., Dorant, E. & van den Brandt, PA. (2000). Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. *Am J Epidemiol.* Vol. 151, No. 6, (March 2000), pp. 541-9, ISSN 0002-9262
- Nilsen, TI. & Vatten, LJ. (1999). Anthropometry and prostate cancer risk: a prospective study of 22,248 Norwegian men. *Cancer Causes Control.* Vol. 10, No. 4, (August 1999), pp. 269-75 ISSN 0957-5243

- Major, JM., Klonoff-Cohen, HS., Pierce, JP., Slymen, DJ., Saltzstein, SL., Macera, CA., Mercola, D. & Kattan MW. (2011). Prostate cancer postoperative nomogram scores and obesity. *PLoS One*. Vol. 6, No. 2, (February 2011), pp. e17382 ISSN 1932-6203
- Hsing, AW., Sakoda, LC. & Chua, S Jr. (2007). Obesity, metabolic syndrome, and prostate cancer. *Am J Clin Nutr*. Vol. 86, No. 3, (September 2007), pp. 843-57, ISSN 0002-9165
- Prabhat, P., Tewari, R., Natu, SM., Dalela, D., Goel, A., Tandon, P., Goel, MM. & Singh, K. Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. *Indian J Urol*. Vol. 26, No. 4, (October 2010), pp. 502-6 ISSN 0970-1591
- Hedlund, TE. & Miller, GJ. (1994). A serum-free defined medium capable of supporting growth of four established human prostatic carcinoma cell lines. *Prostate*. Vol. 24, No. 5, (May 1994), pp. 221-8, ISSN 0270-4137
- Gong, Z., Agalliu, I., Lin, DW., Stanford, JL. & Kristal, AR. (2007) Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. *Cancer*. Vol. 109, No. 6, (March 2007), pp. 1192-202, ISSN 1097-0142
- Freedland, SJ., Grubb, KA., Yiu, SK., Humphreys, EB., Nielsen, ME., Mangold, LA., Isaacs, WB. & Partin, AW. (2005). Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. *J Urol*. Vol. 174, No. 3, (September 2005), pp. 919-22, ISSN 0022-5347
- Cleffi, S., Neto, AS., Reis, LO., Maia, P., Fonseca, F., Wroclawski, ML., Neves, M., Pompeo, AC., Del Giglio, A., Faria, EF. & Tobias-Machado, M. (2011) Androgen Deprivation Therapy And Morbid Obesity: Do They Share Cardiovascular Risk Through Metabolic Syndrome? *Actas Urol Esp*. Vol. 35, No. 5, (May 2011), pp. 259-265, ISSN 0210-4806
- Bryniarski, P., Paradysz, A. & Fryczkowski, M. PSA mass as a marker of prostate cancer progression after radical prostatectomy. (2011). *Med Sci Monit*. Vol. 17, No. 2, (February 2011), pp. 104-9, ISSN 1234-1010
- Boer, P. (1984). Estimated lean body mass as an index for normalization of body fluid volumes in humans. *Am J Physiol*. Vol. 247, No. 4 Pt 2, (October 1984), pp. 632-6, ISSN 0363-6135
- Du Bois, D. & Du Bois, EF. (1916) A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Med*. Vol. 17, No. 5, (October 1916), pp. 863-871, ISSN 0899-9007
- Spangler, E., Zeigler-Johnson, CM., Coomes, M., Malkowicz, SB., Wein, A. & Rebbeck, TR. (2007). Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. *J Urol*. Vol. 178, No. 5, (November 2007), pp. 1939-44, ISSN 0022-5347
- Bray, GA. (2006). Obesity: the disease. *J Med Chem*. Vol. 49, No. 14, (July 2006), pp. 4001-7, ISSN 0022-2623
- Hsing, AW., Reichardt, JK. & Stanczyk, FZ. (2002). Hormones and prostate cancer: current perspectives and future directions. *Prostate*. Vol. 52, No. 3, (August 2002), pp. 213-35, ISSN 0270-4137

- Kaaks, R., Lukanova, A. & Sommersberg, B. (2000). Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. *Prostate Cancer Prostatic Dis.* Vol. 3, No. 3, (November 2000), pp. 157-72, ISSN 1365-7852
- Baillargeon, J., Pollock, BH., Kristal, AR., Bradshaw, P., Hernandez, J., Basler, J., Higgins, B., Lynch, S., Rozanski, T., Troyer, D. & Thompson, I. (2005). The association of body mass index and prostate-specific antigen in a population-based study. *Cancer.* Vol. 103, No. 5, (March 2005), pp. 1092-5, ISSN 1097-0142
- Freedland, SJ., Platz, EA., Presti, JC Jr., Aronson, WJ., Amling, CL., Kane, CJ. & Terris, MK. (2006). Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. *J Urol.* Vol. 175, No. 2, (February 2006), pp. 500-4, ISSN 0022-5347
- Xu, J., Meyers, DA., Sterling, DA., Zheng, SL., Catalona, WJ., Cramer, SD., Bleecker, ER. & Ohar, J. (2002). Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. *Cancer Epidemiol Biomarkers Prev.* Vol. 11, No. 7, (July 2002), pp. 664-9, ISSN 1055-9965

Prostate Cancer - Diagnostic and Therapeutic Advances

Edited by Dr. Philippe E. Spiess

ISBN 978-953-307-319-4

Hard cover, 378 pages

Publisher InTech

Published online 25, November, 2011

Published in print edition November, 2011

In this book entitled "Prostate Cancer - Diagnostic and Therapeutic Advances", we highlight many of the significant advances made in our treatment armamentarium of prostate cancer. The book is subdivided into four sections termed: 1) novel diagnostic approaches, 2) surgical treatments options, 3) radiation therapy and its potential sequelae, and 4) medical management and its treatment complications. After reading the present book, readers will be very familiar with the major clinical advances made in our multifaceted treatment approach to prostate cancer over the past decade. This book is a tribute to our pioneering urologists and allied healthcare professionals who have continually pushed forward our traditional therapeutic envelope.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Piotr Bryniarski, Andrzej Paradysz and Mieczysław Fryczkowski (2011). The Influence of Obesity on Prostate Cancer Diagnosis and Treatment, Prostate Cancer - Diagnostic and Therapeutic Advances, Dr. Philippe E. Spiess (Ed.), ISBN: 978-953-307-319-4, InTech, Available from: <http://www.intechopen.com/books/prostate-cancer-diagnostic-and-therapeutic-advances/the-influence-of-obesity-on-prostate-cancer-diagnosis-and-treatment>

INTeCH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.